Eligibility and cost for Icosapent ethyl based on the REDUCE-IT trial

Authors

Xiaoming Jia, Baylor College of Medicine, USA.
Julia M. Akeroyd, Michael E. DeBakey Veterans Affairs Medical Center, USA.
Khurram Nasir, Yale School of Medicine, USA.
Vijay Nambi, Baylor College of Medicine, USA.
Christie M. Ballantyne, Baylor College of Medicine, USA.
Laura A. Petersen, Michael E. DeBakey Veterans Affairs Medical Center, USA.
Salim S. Virani, Baylor College of Medicine, USA.Follow

Document Type

Article

Department

Office of the Provost; Cardiology

Comments

Abstract is not provided by the author/publisher. This work was published before the author joined Aga Khan University.

Publication (Name of Journal)

Circulation

DOI

10.1161/CIRCULATIONAHA.118.038691

Recommended Citation

Jia, X., Akeroyd, J. M., Nasir, K., Nambi, V., Ballantyne, C. M., Petersen, L. A., Virani, S. S. (2019). Eligibility and cost for Icosapent ethyl based on the REDUCE-IT trial. Circulation, 139(10), 1341-1343.
Available at: https://ecommons.aku.edu/provost_office/662